140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial

Guarneri, V. ; Dieci, M.V. ; Griguolo, G. ; Pare Brunet, L. ; Marin, M. ; Miglietta, F. ; Bottosso, M. ; Giorgi, C.A. ; Blasco, P. ; Castillo, O. ; Galván, P. ; Jares, P. ; Puig-butille, J.A. ; Vivancos, A. ; Villagrasa Gonzalez, P. ; Parker, J. ; Perou, C.M. ; Conte, P.F. ; Prat, A.

Annals of oncology, 2022-09, Vol.33, p.S603 [Periódico revisado por pares]

Texto completo disponível